INC Research, Inc. Strengthens Oncology Team With Two Key Appointments

CAMBERLEY, UK, Jan. 17, 2014 – INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of two senior executives to its oncology team. Asli Turkes, PhD has joined the Company as Vice President, Clinical Development, Oncology and Susan Timoney, PhD has joined as Executive Director, Clinical Development, Oncology. INC Research is organized around therapeutic business units to provide customers with dedicated and experienced teams with leadership specifically aligned to provide optimized strategy and a strong foundation for operational delivery informed by knowledge of the therapy area. Dr. Turkes' and Dr. Timoney's extensive clinical research and oncology-specific expertise further strengthen INC Research's world-class oncology business unit.

Dr. Turkes will be based in the INC Research Camberley, UK office, while Dr. Timoney will be regionally based in Scotland. They will support global trials while also adding dedicated oncology leadership in Europe.

"I am delighted to add these two exceptionally talented individuals to our global oncology team," said Dr. Nick Kenny, Executive Vice President and General Manager, Global Oncology and Hematology at INC Research. "Our oncology practice has experienced considerable growth over the past year, so attracting senior talent of this caliber is an important milestone. Dr. Turkes and Dr. Timoney possess an impressive breadth and depth of understanding of clinical drug development both from a CRO and customer perspective. They will be invaluable in the development and conduct of the highest quality cancer trials for our customers worldwide."

Dr. Turkes brings more than 30 years of clinical research experience, including 14 years with a CRO, where she held roles as a senior project manager, project director, program director, senior director of oncology drug development, and senior customer operations director. She has managed the development of a leading drug for prostate cancer and an orphan drug for Gaucher's disease from preclinical to NDA submission, as well as provided program oversight for two Phase III mega-trials in breast cancer in a monoclonal antibody class drug. Her experience includes all phases of drug development from preclinical to Phase IV, NDA submissions and post-approval studies and her therapeutic experience includes solid tumor indications for prostate, breast, lung, ovarian, melanoma, sarcoma, and haematological oncology indications, such as chemotherapy induced neutrocytopenia, NHL, mantle cell, follicular and CTC lymphoma, ITP, and leukemia. Dr. Turkes also has eight years of academic research and teaching experience as well as nearly a decade of executive management experience.

Dr. Timoney is an experienced clinical research professional with significant expertise in the project delivery of oncology (solid and haematological tumors), internal medicine, respiratory medicine, infectious diseases and CNS research. With more than 18 years of experience in clinical research, including 14 years leading large global/multi-national studies and programs, she has been responsible for the project management of Phase I to IV global studies, from program planning and start-up, to project close-out and review. For the past two years, Dr. Timoney has been leading an enterprise-wide strategic initiative to transform project delivery for a large CRO. Complimentary to her operational and project delivery expertise, Dr. Timoney has significant executive management experience, having been responsible for the general management of a CRO's European operations. Dr. Timoney also has worked in the pharmaceutical sector, where she managed the clinical research department for a specialist pharmaceutical company with key interests in oncology, dermatology, infectious diseases and novel drug delivery mechanisms.

INC Research has conducted more than 600 Phase I through IV oncology trials with nearly 39,000 patients at investigative sites around the globe. The Oncology team works across a broad spectrum of solid tumors and hematologic malignancies, involving all types of drugs in current development. The INC Research Oncology team is currently engaged in cutting-edge hematology-oncology clinical trials, several of which will likely lead to changes in standards of care in the near term. The team is focused on the advancement of scientific knowledge and helping patients through focused, thoughtful management of critical oncology trials. For more information on INC Research's Oncology practice, click here. To read its oncology case studies, click here.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research.